Relmada Therapeutics, Inc.

NASDAQ:RLMD

Biotechnology

Healthcare
$2.86 -0.97%

-$0.06 today

Market cap
$304.61M
Beta
0.39
P/E (TTM)
-9.6
EPS (TTM)
-$0.68
52W Low $0.52High $8.00

Volume 1.86M

Average 1.24M

RLMD Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Relmada Therapeutics, Inc.NASDAQ: RLMD

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue remains negative

Q1 FY2026 deferred revenue was $0, compared with $0 a year earlier.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue vs competitors

How RLMD compares with its peers on the latest reported figures

  • RLMD's Mar 2026 deferred revenue of $0 is the 4th highest of the 9 companies compared; the peer median is $0.
  • Deferred revenue amounts to 0.0% of total assets for RLMD, versus a peer median of 0.0%.
RLMD Competitors Peer median
Deferred Revenue for RLMD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VXRTVaxart, Inc.Mar 2026$11.74M -82.0%—6.5%
TCRXTScan Therapeutics, Inc.Mar 2026$1.64M -84.1%-12.2%0.8%
CBUSCibus, Inc.Mar 2026$449K -48.0%+71.1%0.1%
RLMDRelmada Therapeutics, Inc.Mar 2026$0 ——0.0%
IMUXImmunic, Inc.Mar 2026$0 ——0.0%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
FBIOFortress Biotech, Inc.Mar 2026$0 ——0.0%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
ACETAdicet Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding RLMD) $0-82.0%+29.4%0.0%

Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents44.44M5.4M4.09M3.86M3.5M
Short-term Investments167.47M142.93M92.23M41.05M89.51M
Net Receivables86.38K512.43K000
Inventory00000
Other Current Assets350000
Total Current Assets223.3M152.87M97.51M45.8M93.98M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets28.29K34.88K43.13K21.98K19.5K
Total Non-current Assets28.29K34.88K43.13K21.98K19.5K
Total Assets223.33M152.91M97.55M45.82M94M
Account Payables11.19M5.26M3.51M4.13M1.57M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.64M1.02M5.68M1.15M535.48K
Total Current Liabilities15.06M12.47M12.19M10.29M6.43M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0004.47K1.06M
Total Non-current Liabilities0004.47K1.06M
Total Liabilities15.06M12.47M12.19M10.3M7.49M
Common Stock27.74K30.1K30.1K30.17K73.33K
Retained Earnings(305.07M)(462.11M)(560.9M)(640.88M)(698.27M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity208.26M140.44M85.36M35.52M86.51M
Total Debt00000
Net Debt(44.44M)(5.4M)(4.09M)(3.86M)(3.5M)

Relmada Therapeutics, Inc.

NASDAQ:RLMD

Intrinsic Alpha fair value

Locked

Current Price

$2.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.